Australia markets open in 1 hour 27 minutes

Eli Lilly and Company (0Q1G.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
540.00+295.04 (+120.45%)
At close: 03:18PM GMT
Full screen
Previous close244.96
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Avg. volume4,996
Market cap4.911B
Beta (5Y monthly)0.33
PE ratio (TTM)0.83
EPS (TTM)6.52
Earnings date06 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    13 Best Jim Cramer Stocks To Buy Now

    In this article, we will take a look at the 13 best Jim Cramer stocks to buy now. To see more such companies, go directly to 5 Best Jim Cramer Stocks To Buy Now. Jim Cramer recently talked about the latest market declines and said the buyers are going through a “hangover,” buying the “worst […]

  • PR Newswire

    Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium

    Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS). MONARCH 3 evaluated Verzenio® (abemaciclib) in combination with an aromatase inhibitor (AI) compared to an AI alone as initial endocrine-based therapy for post-menopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or me

  • Reuters

    Eli Lilly obesity drug now available in US pharmacies

    (Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danuglipron into late-stage clinical trials after most patients dropped out of a midstage trial with high rates of side effects such as nausea and vomiting.